TY  - JOUR
UR  - http://www.badankebijakan.kemkes.go.id/repositori/id/eprint/1067/
KW  - malaria; antimalarials; multidrug resistance; buletin penelitian kesehatan; P5-BPPK
SN  - 0125-9695
ID  - bkpkkemkes1067
PB  - Badan Penelitian dan Pengembangan Kesehatan
Y1  - 1997///
JF  - Buletin Penelitian Kesehatan
TI  - Tinjauan Hasil Uji Coba Pengobatan dan Pencegahan Malaria di Beberapa Tempat Indonesia, 1986-1995
VL  - 25
AV  - public
IS  - 3&4
A1  - Tjitra, Emilliana
N2  - In Indonesia, only antimalarials chloroquine/sulfadoxine/sulfalene-pyrimethamine, quinine, and primaguine are available. The development of chloroquine and multidrug resistance poses a therapeutic challenge. In order to obtain alternative antimalarial drugs, trials were conducted of malaria treatment and prophylaxis in several chloroqiune or multidrug resistance areas. The objective of these trials was to asses the efficacy and safety of the alternative antimalarial drugs.      All the trials were mostly open studies in the fields and hospitals. These were collaboration studies between Communicable Diseases Research Center, Communicable Diseases  Control and Environmental Health, Faculty of Medicine of the University of Indonesia, NAMRU-2, and local health staff.       The patients were selected according to the WHO criteria for in-vivo antimalarial drug sensitivity testing. The should sign the informed consent form and they were followed up during the study, for 2 weeks-4 months.      In chloroquine and multidrug resistance areas, mefloquine, haloquine, and artemether are effective and safe for treatment of uncomplicated falciparum malaria. While artesunate was noted effective and safe only in the first 14 days. Halofantrine was also documented effective and safe for vivax malaria treatment. Intramuscular artemether was effective and safe for treatment of  severe and complicated falciparum malaria, particulary in remote areas lacking hospitals and the capacity for intravenous infusion. Primaguine, doxycycline and mefloquine are effective are safe for malaria prophylaxis.      Since the new antimalarials are not yet available in Indonesia, the improvement of efficacy of antimalarial drugs currently available shoulds be studied. Prophylactic drugs which are effective and safe for children, pregnant and lactating women should also be studied.
ER  -